HIMS stock soars to all-time high, reaching $35.07

In a remarkable display of market confidence, HIMS & Hers Health, Inc. (HIMS) stock has soared to an all-time high, reaching a price level of $35.07. This significant milestone underscores the company’s robust performance and investor optimism in its business model and growth prospects. The health and wellness brand, known for its direct-to-consumer telehealth and wellness products, has been riding a wave of positive sentiment, with revenue growth of 56.7% in the last twelve months and an "GREAT" financial health score according to InvestingPro. While the company is currently trading slightly above its Fair Value, investors can access 18 additional exclusive ProTips and a comprehensive Pro Research Report for HIMS on InvestingPro. Meanwhile, in a separate but equally impressive feat, Oaktree Acquisition Corp (NYSE:HIMS) has witnessed a staggering 1-year change, with its stock value climbing by 289.23%, signaling a bullish market stance on the company’s future.

In other recent news, Hims & Hers Health has seen significant developments in earnings and revenue results, as well as analyst ratings. The company reported a 77% year-over-year increase in Q3 sales, surpassing $400 million, with an adjusted EBITDA over $50 million. Revenue projections for Q4 2024 range between $465 million and $470 million, indicating a significant year-over-year increase. On the analyst front, BofA Securities maintained an Underperform rating on Hims & Hers, citing concerns about the future of the company’s compounded GLP-1 products. In contrast, BTIG initiated coverage with a Buy rating, highlighting robust revenue growth. Needham & Company named Hims & Hers a top pick for 2025, while Morgan Stanley (NYSE:MS) also initiated coverage with an Overweight rating. Other company news includes a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound. These are recent developments, reflecting the ongoing evolution of Hims & Hers Health’s business strategy and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.